Trials / Completed
CompletedNCT06344793
Initial CDK 4/6 Inhibitor Plus Endocrine Therapy Versus Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer
A Multi-center Study of the Clinical Outcomes Between Initial CDK 4/6 Inhibitor Plus Endocrine Therapy and Initial Chemotherapy in HR Positive, HER2 Negative Unresectable or Metastatic Breast Cancer in Real World Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 608 (actual)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- —
Summary
A multi-center, real world study to evaluate the clinical outcomes between initial CDK 4/6 Inhibitor plus endocrine therapy and initial chemotherapy in HR positive, HER2 negative unresectable or metastatic breast cancer.
Conditions
Timeline
- Start date
- 2023-05-20
- Primary completion
- 2024-10-01
- Completion
- 2025-02-01
- First posted
- 2024-04-03
- Last updated
- 2025-07-28
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06344793. Inclusion in this directory is not an endorsement.